Mindsense Biosystems

Mindsense Biosystems, which later rebranded as Ridge Diagnostics, was a biotechnology company focused on developing blood-based diagnostic tests for neuropsychiatric disorders. The company's flagship product was the first objective blood test for Major Depressive Disorder (MDD), utilizing a proprietary multi-biomarker panel to provide clinicians with quantitative data. By measuring specific biological markers associated with depression, the technology aimed to improve diagnostic accuracy and treatment monitoring beyond traditional subjective assessments. The company was acquired by Myriad Genetics in 2014 to expand their personalized medicine portfolio into the mental health space.